Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development
暂无分享,去创建一个
R. Simon | T. Fojo | S. Bates | T. Vidaurre | J. Wilkerson | R. Simon
[1] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[2] C. García-echeverría,et al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. , 2009, Current opinion in cell biology.
[3] Thomas S. Lin,et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. , 2009, Blood.
[4] D. Cella,et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Eisenhauer,et al. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Jeffrey W. Clark,et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.
[9] Thomas S. Lin,et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.
[10] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[11] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[12] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[13] Dongsheng Tu,et al. Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval , 2005, Clinical Cancer Research.
[14] Suzanne F. Jones,et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Eisenhauer. Special Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism , 2005 .
[16] Giampietro Gasparini,et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Mark J Ratain,et al. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Swaisland,et al. Development of the Novel Biologically Targeted Anticancer Agent Gefitinib , 2004, Clinical Cancer Research.
[19] M. Ratain,et al. Development of Target-Based Antineoplastic Agents , 2000, Investigational New Drugs.
[20] M. Hidalgo,et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Thomas J Lynch,et al. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M J Ratain,et al. Clinical trial designs for cytostatic agents. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[25] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[26] A. Harris,et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.